Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
- PMID: 29960205
- DOI: 10.1016/j.ejmech.2018.06.014
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
Abstract
The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection.
Keywords: Cefiderocol; Multi-drug resistant Gram-negative pathogens; Siderophore; Siderophore cephalosporin.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
-
Cefiderocol: A Siderophore Cephalosporin.Ann Pharmacother. 2020 Dec;54(12):1215-1231. doi: 10.1177/1060028020929988. Epub 2020 Jun 10. Ann Pharmacother. 2020. PMID: 32522005 Review.
-
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.Int J Antimicrob Agents. 2019 Apr;53(4):456-466. doi: 10.1016/j.ijantimicag.2018.11.007. Epub 2018 Nov 22. Int J Antimicrob Agents. 2019. PMID: 30471402
-
Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.Pharmacotherapy. 2020 Dec;40(12):1228-1247. doi: 10.1002/phar.2476. Epub 2020 Nov 19. Pharmacotherapy. 2020. PMID: 33068441 Review.
-
An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria.Mini Rev Med Chem. 2020;20(18):1908-1916. doi: 10.2174/1389557520666200818211405. Mini Rev Med Chem. 2020. PMID: 32811410 Review.
Cited by
-
In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.Eur J Clin Microbiol Infect Dis. 2022 Dec;41(12):1451-1457. doi: 10.1007/s10096-022-04503-7. Epub 2022 Oct 6. Eur J Clin Microbiol Infect Dis. 2022. PMID: 36201141
-
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538-S543. doi: 10.1093/cid/ciz826. Clin Infect Dis. 2019. PMID: 31724047 Free PMC article. Review.
-
Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.EMBO Rep. 2023 Jan 9;24(1):e56033. doi: 10.15252/embr.202256033. Epub 2022 Dec 19. EMBO Rep. 2023. PMID: 36533629 Free PMC article. Review.
-
Thienopyrimidinone Derivatives That Inhibit Bacterial tRNA (Guanine37-N1)-Methyltransferase (TrmD) by Restructuring the Active Site with a Tyrosine-Flipping Mechanism.J Med Chem. 2019 Sep 12;62(17):7788-7805. doi: 10.1021/acs.jmedchem.9b00582. Epub 2019 Aug 29. J Med Chem. 2019. PMID: 31442049 Free PMC article.
-
Chelation in Antibacterial Drugs: From Nitroxoline to Cefiderocol and Beyond.Antibiotics (Basel). 2022 Aug 15;11(8):1105. doi: 10.3390/antibiotics11081105. Antibiotics (Basel). 2022. PMID: 36009974 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous